The Pelvic Floor Is a Problem
Everyone’s suddenly obsessed with the pelvic floor—physical therapists, MAHA influencers, me. Could this deeply misunderstood body part really be the seat of so much modern dysfunction?
The Mysterious Math Behind the Brazilian Butt Lift
For years, plastic surgeons thought the proportions of a beautiful buttocks should follow the Fibonacci sequence. Now, people are looking for a more Kardashian shape.
The Cure
Every day, millions confide in AI, exposing their most intimate problems and hoping it will fix them. This is the story of two people—and their bots—on the very edge of therapy’s new frontier.
AI’s Next Frontier? An Algorithm for Consciousness
Some of the world’s most interesting thinkers about thinking think they might’ve cracked machine sentience. And I think they might be onto something.
Elon Musk Is Out to Rule Space. Can Anyone Stop Him?
With SpaceX and Starlink, Elon Musk controls more than half the world’s rocket launches and thousands of internet satellites. That amounts to immense geopolitical power.
There’s Neuralink—and There’s the Mind-Reading Company That Might Surpass It
Unlike Elon Musk's brain-computer interface, Synchron's doesn't require open-skull surgery, and it has an OpenAI chatbot baked in.
The Next Thing You Smell Could Ruin Your Life
Millions of people suffer debilitating reactions in the presence of certain scents and chemicals. One scientist has been struggling for decades to understand why—as she battles the condition herself.
Where Are All the AI Drugs?
In an industry where 90 percent of drug candidates fail before reaching the market, a handful of startups are betting everything on AI to beat the odds.
Cloning Came to Polo. Then Things Got Truly Uncivilized
A polo legend and a businessman joined forces to copy the player’s greatest horse. But with a single clone worth $800,000, some technologies are a breeding ground for betrayal.
The King of Ozempic Is Scared as Hell
Now that Novo Nordisk is the world’s weight-loss juggernaut, will it have to betray its first patients—type 1 diabetics?